Acetylcysteine

Last updated

Acetylcysteine
Acetylcysteine2DACS.svg
Acetylcysteine-from-xtal-3D-bs-17.png
Clinical data
Pronunciation /əˌsiːtəlˈsɪstiːn/ and similar ( /əˌsɛtəl-,ˌæsɪtəl-,-tiːn/ )
Trade names ACC 200, Acetadote, Fluimucil, Mucomyst, others
Other namesN-acetylcysteine; N-acetyl-L-cysteine; NALC; NAC
AHFS/Drugs.com Monograph
License data
Pregnancy
category
  • AU:B2
Routes of
administration 		By mouth, intravenous, inhalation
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 10% (Oral) [6]
Protein binding 50 to 83% [7]
Metabolism Liver [7]
Elimination half-life 5.6 hours [5]
Excretion Kidney (30%), [7] faecal (3%)
Identifiers
  • (2R)-2-acetamido-3-sulfanylpropanoic acid [8]
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.009.545 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C5H9NO3S
Molar mass 163.19 g·mol−1
3D model (JSmol)
Specific rotation +5° (c = 3% in water) [9]
Melting point 109 to 110 °C (228 to 230 °F) [9]
  • C/C(=N/[C@@H](CS)C(=O)O)/O
  • InChI=1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1 Yes check.svgY
  • Key:PWKSKIMOESPYIA-BYPYZUCNSA-N Yes check.svgY
   (verify)

Acetylcysteine, also known as N-acetylcysteine (NAC), is a medication that is used to treat paracetamol overdose and to loosen thick mucus in individuals with chronic bronchopulmonary disorders like pneumonia and bronchitis. [7] It has been used to treat lactobezoar in infants. It can be taken intravenously, by mouth, or inhaled as a mist. [7] Some people use it as a dietary supplement. [10] [11]

Contents

Common side effects include nausea and vomiting when taken by mouth. [7] The skin may occasionally become red and itchy with any route of administration. [7] A non-immune type of anaphylaxis may also occur. [7] It appears to be safe in pregnancy. [7] For paracetamol overdose, it works by increasing the level of glutathione, an antioxidant that can neutralise the toxic breakdown products of paracetamol. [7] When inhaled, it acts as a mucolytic by decreasing the thickness of mucus. [12]

Acetylcysteine was initially patented in 1960 and came into medical use in 1968. [13] [14] [15] It is on the World Health Organization's List of Essential Medicines. [16] [17] It is available as a generic medication. [18]

The sulfur-containing amino acids cysteine and methionine are more easily oxidized than the other amino acids. [19] [20]

Uses

Medical uses

Paracetamol overdose

Intravenous and oral formulations of acetylcysteine are available for the treatment of paracetamol (acetaminophen) overdose. [21] When paracetamol is taken in large quantities, a minor metabolite called N-acetyl-p-benzoquinone imine (NAPQI) accumulates within the body. It is normally conjugated by glutathione, but when taken in excess, the body's glutathione reserves are not sufficient to deactivate the toxic NAPQI. This metabolite is then free to react with key hepatic enzymes, thereby damaging liver cells. This may lead to severe liver damage and even death by acute liver failure.

In the treatment of paracetamol (acetaminophen) overdose, acetylcysteine acts to maintain or replenish depleted glutathione reserves in the liver and enhance non-toxic metabolism of acetaminophen. [22] These actions serve to protect liver cells from NAPQI toxicity. It is most effective in preventing or lessening hepatic injury when administered within 8–10 hours after overdose. [22] Research suggests that the rate of liver toxicity is approximately 3% when acetylcysteine is administered within 10 hours of overdose. [21]

Although IV and oral acetylcysteine are equally effective for this indication, oral administration is generally poorly tolerated due to the higher dosing required to overcome its low oral bioavailability, [23] its foul taste and odour, and a higher incidence of adverse effects when taken by mouth, particularly nausea and vomiting. Prior pharmacokinetic studies of acetylcysteine did not consider acetylation as a reason for the low bioavailability of acetylcysteine. [24] Oral acetylcysteine is identical in bioavailability to cysteine precursors. [24] However, 3% to 6% of people given intravenous acetylcysteine show a severe, anaphylaxis-like allergic reaction, which may include extreme breathing difficulty (due to bronchospasm), a decrease in blood pressure, rash, angioedema, and sometimes also nausea and vomiting. [25] Repeated doses of intravenous acetylcysteine will cause these allergic reactions to progressively worsen in these people.

Several studies have found this anaphylaxis-like reaction to occur more often in people given intravenous acetylcysteine despite serum levels of paracetamol not high enough to be considered toxic. [26] [27] [28] [29]

Lungs

Inhaled acetylcysteine has been used for mucolytic ("mucus-dissolving") therapy in addition to other therapies in respiratory conditions with excessive and/or thick mucus production. It is also used post-operatively, as a diagnostic aid, and in tracheotomy care. It may be considered ineffective in cystic fibrosis. [30] A 2013 Cochrane review in cystic fibrosis found no evidence of benefit. [31]

Acetylcysteine is used in the treatment of obstructive lung disease as an adjuvant treatment. [32] [33] [34]

Other uses

Acetylcysteine has been used to complex palladium, to help it dissolve in water. This helps to remove palladium from drugs or precursors synthesized by palladium-catalyzed coupling reactions. [35] N-acetylcysteine can be used to protect the liver. [36]

Microbiological use

Acetylcysteine can be used in Petroff's method of liquefaction and decontamination of sputum, in preparation for recovery of mycobacterium. [37] It also displays significant antiviral activity against the influenza A viruses. [38]

Acetylcysteine has bactericidal properties and breaks down bacterial biofilms of clinically relevant pathogens including Pseudomonas aeruginosa , Staphylococcus aureus , Enterococcus faecalis , Enterobacter cloacae , Staphylococcus epidermidis , and Klebsiella pneumoniae . [39]

Side effects

The most commonly reported adverse effects for IV formulations of acetylcysteine are rash, urticaria, and itchiness. [22]

Adverse effects for inhalational formulations of acetylcysteine include nausea, vomiting, stomatitis, fever, rhinorrhea, drowsiness, clamminess, chest tightness, and bronchoconstriction. Although infrequent, bronchospasm has been reported to occur unpredictably in some patients. [40]

Adverse effects for oral formulations of acetylcysteine have been reported to include nausea, vomiting, rash, and fever. [40]

Large doses in a mouse model showed that acetylcysteine could potentially cause damage to the heart and lungs. [41] They found that acetylcysteine was metabolized to S-nitroso-N-acetylcysteine (SNOAC), which increased blood pressure in the lungs and right ventricle of the heart (pulmonary artery hypertension) in mice treated with acetylcysteine. The effect was similar to that observed following a 3-week exposure to an oxygen-deprived environment (chronic hypoxia). The authors also found that SNOAC induced a hypoxia-like response in the expression of several important genes both in vitro and in vivo .

The implications of these findings for long-term treatment with acetylcysteine have not yet been investigated. The dose used by Palmer and colleagues was dramatically higher than that used in humans, the equivalent of about 20 grams per day. [41] In humans, a much lower dosages (600 mg per day) have been observed to counteract some age-related decline in the hypoxic ventilatory response as tested by inducing prolonged hypoxia. [42]

Although N-acetylcysteine prevented liver damage in mice when taken before alcohol, when taken four hours after alcohol it made liver damage worse in a dose-dependent fashion. [43]

Pharmacology

Pharmacodynamics

Acetylcysteine serves as a prodrug to L-cysteine, a precursor to the biologic antioxidant glutathione. Hence administration of acetylcysteine replenishes glutathione stores. [44]

L-cysteine also serves as a precursor to cystine, which in turn serves as a substrate for the cystine-glutamate antiporter on astrocytes; hence there is increasing glutamate release into the extracellular space. This glutamate in turn acts on mGluR2/3 receptors, and at higher doses of acetylcysteine, mGluR5. [50] [51] Acetylcysteine may have other biological functions in the brain, such as the modulation of dopamine release and the reduction in inflammatory cytokine formation possibly via inhibiting NF-κB and modulating cytokine synthesis. [48] These properties, along with the reduction of oxidative stress and the re‐establishment of glutamatergic balance, would lead to an increase in growth factors, such as brain‐derived neurotrophic factor (BDNF), and the regulation of neuronal cell death through B‐cell lymphoma 2 expression (BLC-2). [52]

Pharmacokinetics

Acetylcysteine is extensively liver metabolized, CYP450 minimal, urine excretion is 22–30% with a half-life of 5.6 hours in adults and 11 hours in newborns.

Chemistry

Acetylcysteine is the N-acetyl derivative of the amino acid L-cysteine, and is a precursor in the formation of the antioxidant glutathione in the body. The thiol (sulfhydryl) group confers antioxidant effects and is able to reduce free radicals.

N-acetyl-L-cysteine is soluble in water and alcohol, and practically insoluble in chloroform and ether. [53]

It is a white to white with light yellow cast powder, and has a pKa of 9.5 at 30 °C. [9]

Society and culture

Acetylcysteine was first studied as a drug in 1963. Amazon removed acetylcysteine for sale in the US in 2021, due to claims by the FDA of it being classified as a drug rather than a supplement. [54] [55] [56] [57] In April 2022, the FDA released draft guidance on FDA's policy regarding products labeled as dietary supplements that contain N-acetyl-L-cysteine. [58] Amazon subsequently re-listed NAC products as of August 2022. [59]

Research

While many antioxidants have been researched to treat a large number of diseases by reducing the negative effect of oxidative stress, acetylcysteine is one of the few that has yielded promising results, and is currently already approved for the treatment of paracetamol overdose. [60]

Kidney and bladder

Evidence for the benefit of acetylcysteine to prevent radiocontrast induced kidney disease is mixed. [73]

Acetylcysteine has been used for cyclophosphamide-induced haemorrhagic cystitis, although mesna is generally preferred due to the ability of acetylcysteine to diminish the effectiveness of cyclophosphamide. [74]

Psychiatry

Acetylcysteine has been studied for major psychiatric disorders, [75] [52] [48] [62] including bipolar disorder, [75] major depressive disorder, and schizophrenia. [52] [48]

Tentative evidence exists for N-acetylcysteine also in the treatment of Alzheimer's disease, autism, obsessive-compulsive disorder, [76] specific drug addictions (cocaine), drug-induced neuropathy, trichotillomania, excoriation disorder, and a certain form of epilepsy (progressive myoclonic). [52] [48] [77] Preliminary evidence showed efficacy in anxiety disorder, attention deficit hyperactivity disorder and mild traumatic brain injury although confirmatory studies are required. [77] [78] [79] [80] Tentative evidence also supports use in cannabis use disorder. [81]

It is also being studied for use as a treatment of body-focused repetitive behavior. [82] [83]

Addiction

Evidence to date does not support the efficacy for N-acetylcysteine in treating addictions to gambling, methamphetamine, or nicotine. [77] Based upon limited evidence, NAC appears to normalize glutamate neurotransmission in the nucleus accumbens and other brain structures, in part by upregulating the expression of excitatory amino acid transporter 2 (EAAT2), a.k.a. glutamate transporter 1 (GLT1), in individuals with addiction. [69] While NAC has been demonstrated to modulate glutamate neurotransmission in adult humans who are addicted to cocaine, NAC does not appear to modulate glutamate neurotransmission in healthy adult humans. [69] NAC has been hypothesized to exert beneficial effects through its modulation of glutamate and dopamine neurotransmission as well as its antioxidant properties. [48]

Bipolar disorder

In bipolar disorder, N-acetylcysteine has been repurposed as an augmentation strategy for depressive episodes in light of the possible role of inflammation in the pathogenesis of mood disorders. Nonetheless, meta-analytic evidence shows that add-on N-acetylcysteine was more effective than placebo only in reducing depression scales scores (low quality evidence), without positive effects on response and remission outcomes, limiting its possible role in clinical practice to date. [75] [84]

COVID-19

Acetylcysteine is being considered as a possible treatment for COVID-19. [85] [86] [87]

A combination of guanfacine and N-acetylcysteine has been found to lift the "brain fog" of eight patients with long COVID, according to researchers. [88]

A combination of glycine and N-acetylcysteine is suspected to have potential to safely replenish depleted glutathione levels in COVID-19 patients. [89]

Related Research Articles

<span class="mw-page-title-main">Ketamine</span> Dissociative anesthetic and anti-depressant

Ketamine is a dissociative anesthetic used medically for induction and maintenance of anesthesia. It is also used as a treatment for depression and pain management. It is a novel compound that was derived from phencyclidine in 1962 in pursuit of a safer anesthetic with fewer hallucinogenic effects.

<span class="mw-page-title-main">Glutathione</span> Ubiquitous antioxidant compound in living organisms

Glutathione is an antioxidant in plants, animals, fungi, and some bacteria and archaea. Glutathione is capable of preventing damage to important cellular components caused by sources such as reactive oxygen species, free radicals, peroxides, lipid peroxides, and heavy metals. It is a tripeptide with a gamma peptide linkage between the carboxyl group of the glutamate side chain and cysteine. The carboxyl group of the cysteine residue is attached by normal peptide linkage to glycine.

<span class="mw-page-title-main">Paracetamol</span> Common medication for pain and fever

Paracetamol is a non-opioid analgesic and antipyretic agent used to treat fever and mild to moderate pain. It is a widely used over the counter medication. Common brand names include Tylenol and Panadol.

<span class="mw-page-title-main">Riluzole</span> Medication used to treat amyotrophic lateral sclerosis

Riluzole is a medication used to treat amyotrophic lateral sclerosis and other motor neuron diseases. Riluzole delays the onset of ventilator-dependence or tracheostomy in some people and may increase survival by two to three months. Riluzole is available in tablet and liquid form.

<span class="mw-page-title-main">Neuroprotection</span> Relative preservation of neuronal structure and/or function

Neuroprotection refers to the relative preservation of neuronal structure and/or function. In the case of an ongoing insult the relative preservation of neuronal integrity implies a reduction in the rate of neuronal loss over time, which can be expressed as a differential equation. It is a widely explored treatment option for many central nervous system (CNS) disorders including neurodegenerative diseases, stroke, traumatic brain injury, spinal cord injury, and acute management of neurotoxin consumption. Neuroprotection aims to prevent or slow disease progression and secondary injuries by halting or at least slowing the loss of neurons. Despite differences in symptoms or injuries associated with CNS disorders, many of the mechanisms behind neurodegeneration are the same. Common mechanisms of neuronal injury include decreased delivery of oxygen and glucose to the brain, energy failure, increased levels in oxidative stress, mitochondrial dysfunction, excitotoxicity, inflammatory changes, iron accumulation, and protein aggregation. Of these mechanisms, neuroprotective treatments often target oxidative stress and excitotoxicity—both of which are highly associated with CNS disorders. Not only can oxidative stress and excitotoxicity trigger neuron cell death but when combined they have synergistic effects that cause even more degradation than on their own. Thus limiting excitotoxicity and oxidative stress is a very important aspect of neuroprotection. Common neuroprotective treatments are glutamate antagonists and antioxidants, which aim to limit excitotoxicity and oxidative stress respectively.

Chronic liver disease in the clinical context is a disease process of the liver that involves a process of progressive destruction and regeneration of the liver parenchyma leading to fibrosis and cirrhosis. "Chronic liver disease" refers to disease of the liver which lasts over a period of six months. It consists of a wide range of liver pathologies which include inflammation, liver cirrhosis, and hepatocellular carcinoma. The entire spectrum need not be experienced.

<span class="mw-page-title-main">Cysteamine</span> Chemical compound

Cysteamine is a chemical compound that can be biosynthesized in mammals, including humans, by the degradation of coenzyme A. The intermediate pantetheine is broken down into cysteamine and pantothenic acid. It is the biosynthetic precursor to the neurotransmitter hypotaurine.

<span class="mw-page-title-main">NAPQI</span> Toxic byproduct of acetaminophen

NAPQI, also known as NAPBQI or N-acetyl-p-benzoquinone imine, is a toxic byproduct produced during the xenobiotic metabolism of the analgesic paracetamol (acetaminophen). It is normally produced only in small amounts, and then almost immediately detoxified in the liver.

<span class="mw-page-title-main">Glutathione synthetase</span> Enzyme

Glutathione synthetase (GSS) is the second enzyme in the glutathione (GSH) biosynthesis pathway. It catalyses the condensation of gamma-glutamylcysteine and glycine, to form glutathione. Glutathione synthetase is also a potent antioxidant. It is found in many species including bacteria, yeast, mammals, and plants.

<span class="mw-page-title-main">Allopregnanolone</span> Endogenous inhibitory neurosteroid

Allopregnanolone is a naturally occurring neurosteroid which is made in the body from the hormone progesterone. As a medication, allopregnanolone is referred to as brexanolone, sold under the brand name Zulresso, and used to treat postpartum depression. It is given by injection into a vein.

<span class="mw-page-title-main">Quisqualic acid</span> Chemical compound

Quisqualic acid is an agonist of the AMPA, kainate, and group I metabotropic glutamate receptors. It is one of the most potent AMPA receptor agonists known. It causes excitotoxicity and is used in neuroscience to selectively destroy neurons in the brain or spinal cord. Quisqualic acid occurs naturally in the seeds of Quisqualis species.

<span class="mw-page-title-main">Thiocolchicoside</span> Chemical compound

Thiocolchicoside is a muscle relaxant with anti-inflammatory and analgesic effects. Its mechanism of action is unknown, but it is believed to be act via antagonism of nicotinic acetylcholine receptors (nAchRs). However, it also appears to be a competitive antagonist of GABAA and glycine receptors. As such, it has powerful convulsant activity and should not be used in seizure-prone individuals.

<span class="mw-page-title-main">Bucillamine</span> Chemical compound

Bucillamine is an antirheumatic agent developed from tiopronin. Activity is mediated by the two thiol groups that the molecule contains. Research done in USA showed positive transplant preservation properties. Bucillamine is currently being investigated for COVID-19 drug repurposing.

<span class="mw-page-title-main">NFE2L2</span> Human protein and coding gene

Nuclear factor erythroid 2-related factor 2 (NRF2), also known as nuclear factor erythroid-derived 2-like 2, is a transcription factor that in humans is encoded by the NFE2L2 gene. NRF2 is a basic leucine zipper (bZIP) protein that may regulate the expression of antioxidant proteins that protect against oxidative damage triggered by injury and inflammation, according to preliminary research. In vitro, NRF2 binds to antioxidant response elements (AREs) in the promoter regions of genes encoding cytoprotective proteins. NRF2 induces the expression of heme oxygenase 1 in vitro leading to an increase in phase II enzymes. NRF2 also inhibits the NLRP3 inflammasome.

Glutamate–cysteine ligase (GCL) EC 6.3.2.2), previously known as γ-glutamylcysteine synthetase (GCS), is the first enzyme of the cellular glutathione (GSH) biosynthetic pathway that catalyzes the chemical reaction:

<span class="mw-page-title-main">Cystine/glutamate transporter</span> Protein found in humans

Cystine/glutamate transporter is an antiporter that in humans is encoded by the SLC7A11 gene.

<span class="mw-page-title-main">Paracetamol poisoning</span> Toxicity due to paracetamol overdose

Paracetamol poisoning, also known as acetaminophen poisoning, is caused by excessive use of the medication paracetamol (acetaminophen). Most people have few or non-specific symptoms in the first 24 hours following overdose. These symptoms include feeling tired, abdominal pain, or nausea. This is typically followed by absence of symptoms for a couple of days, after which yellowish skin, blood clotting problems, and confusion occurs as a result of liver failure. Additional complications may include kidney failure, pancreatitis, low blood sugar, and lactic acidosis. If death does not occur, people tend to recover fully over a couple of weeks. Without treatment, death from toxicity occurs 4 to 18 days later.

<span class="mw-page-title-main">Acetylcarnosine</span> Chemical compound

N-Acetylcarnosine (NAC) is a naturally occurring compound chemically related to the dipeptide carnosine. The NAC molecular structure is identical to carnosine with the exception that it carries an additional acetyl group. The acetylation makes NAC more resistant to degradation by carnosinase, an enzyme that breaks down carnosine to its constituent amino acids, beta-alanine and histidine.

<span class="mw-page-title-main">Nitrotyrosine</span> Chemical compound

Nitrotyrosine is a product of tyrosine nitration mediated by reactive nitrogen species such as peroxynitrite anion and nitrogen dioxide. Nitrotyrosine is identified as an indicator or marker of cell damage, inflammation as well as NO (nitric oxide) production. Nitrotyrosine is formed in the presence of the active metabolite NO. Generally in many disease states, oxidative stress increases the production of superoxide (O2−) and NO forming peroxynitrite (ONOO−) a destructive free radical oxidant. The production of ONOO− is capable of oxidizing several lipoproteins and of nitrating tyrosine residues in many proteins. It is difficult to determine the production of ONOO− so, usually nitrotyrosine in proteins are the detectable marker for indirectly detecting ONOO−. It is detected in large number of pathological conditions and is considered a marker of NO-dependent, reactive nitrogen species-induced nitrative stress. Nitrotyrosine is detected in biological fluids such as plasma, lung aspirants-BALF (Broncho alveolar lining fluid) and urine. Increased level of nitrotyrosine is detected in rheumatoid arthritis, septic shock and coeliac disease. In all these studies nitrotyrosine was undetected in healthy subjects. Nitrotyrosine is also found in numerous other disease-affected tissues, such as the cornea in keratoconus. Peroxynitrite and/or nitrative stress may participate in the pathogenesis of diabetes.

<span class="mw-page-title-main">Boldine</span> Chemical compound

Boldine is an alkaloid of the aporphine class that can be found in the boldo tree. It is the most abundant aporphine alkaloid found in Boldo. Boldine is also found in Lindera aggregata.

References

  1. ↑ DBL ACETYLCYSTEINE injection concentrate acetylcysteine 2 g/ 10 mL injection ampoule
  2. ↑ "TGA eBS - Product and Consumer Medicine Information Licence".
  3. ↑ "Acetylcysteine (Omegapharm)". Healthdirect Australia. 30 November 2022. Retrieved 29 December 2022.
  4. ↑ "Acepiro 600 mg effervescent tablets - Summary of Product Characteristics (SmPC)". (emc). 30 August 2022. Retrieved 29 December 2022.
  5. 1 2 "Acetadote- acetylcysteine injection, solution". DailyMed. 1 October 2021. Retrieved 29 December 2022.
  6. ↑ Stockley RA (2008). Chronic Obstructive Pulmonary Disease a Practical Guide to Management. Chichester: John Wiley & Sons. p. 750. ISBN   9780470755280. Archived from the original on 8 September 2017.
  7. 1 2 3 4 5 6 7 8 9 10 "Acetylcysteine". The American Society of Health-System Pharmacists. Archived from the original on 23 September 2015. Retrieved 22 August 2015.
  8. ↑ "L-Cysteine, N-acetyl- — Compound Summary". PubChem. National Center for Biotechnology Information, U.S. National Library of Medicine. 25 March 2005. Identification. Archived from the original on 12 January 2014. Retrieved 9 January 2012.
  9. 1 2 3 "N-Acetyl-L-cysteine Product Information" (PDF). Sigma. Sigma-Aldrich. Archived from the original (PDF) on 11 June 2014. Retrieved 9 November 2014.
  10. ↑ Talbott SM (2012). A Guide to Understanding Dietary Supplements. Routledge. p. 469. ISBN   9781136805707. Archived from the original on 8 September 2017.
  11. ↑ "Cysteine". University of Maryland Medical Center. Archived from the original on 1 July 2017. Retrieved 23 June 2017.
  12. ↑ Sadowska AM, Verbraecken J, Darquennes K, De Backer WA (December 2006). "Role of N-acetylcysteine in the management of COPD". International Journal of Chronic Obstructive Pulmonary Disease. 1 (4): 425–434. doi: 10.2147/copd.2006.1.4.425 . ISSN   1176-9106. PMC   2707813 . PMID   18044098.
  13. ↑ Fischer J, Ganellin CR (2006). Analogue-Based Drug Discovery. Weinheim: Wiley-VCH. p. 544. ISBN   9783527607495. Archived from the original on 8 September 2017.
  14. ↑ US3091569A,Leonard, Sheffner Aaron,"Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus",issued 28 May 1963
  15. ↑ USpatent 3091569,Aaron Leonard Sheffner,"Mucolytic-N-acylated sulfhydryl compositions and process for treating animal mucus",published 28 May 1963,issued 28 May 1963, assigned to Mead Johnson & Co
  16. ↑ World Health Organization Model List of Essential Medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  17. ↑ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl: 10665/345533 . WHO/MHP/HPS/EML/2021.02.
  18. ↑ Baker E (2014). "Acetylcysteine". Top 100 Drugs: Clinical pharmacology and practical prescribing. Elsevier Health Sciences. ISBN   9780702055157. Archived from the original on 8 September 2017.
  19. ↑ Bin P, Huang R, Zhou X (2017). "Oxidation Resistance of the Sulfur Amino Acids: Methionine and Cysteine". BioMed Research International. 2017: 9584932. doi: 10.1155/2017/9584932 . PMC   5763110 . PMID   29445748.
  20. ↑ Lee BC, Dikiy A, Kim HY, Gladyshev VN (2009). "Functions and evolution of selenoprotein methionine sulfoxide reductases". Biochimica et Biophysica Acta (BBA) - General Subjects. 1790 (11): 1471–1477. doi:10.1016/j.bbagen.2009.04.014. PMC   3062201 . PMID   19406207.
  21. 1 2 Green JL, Heard KJ, Reynolds KM, Albert D (May 2013). "Oral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis". The Western Journal of Emergency Medicine. 14 (3): 218–226. doi:10.5811/westjem.2012.4.6885. PMC   3656701 . PMID   23687539.
  22. 1 2 3 "Acetadote Package Insert" (PDF). FDA. Archived (PDF) from the original on 25 August 2013. Retrieved 19 April 2014.
  23. ↑ Borgström L, Kågedal B, Paulsen O (1986). "Pharmacokinetics of N-acetylcysteine in man". European Journal of Clinical Pharmacology. 31 (2): 217–222. doi:10.1007/bf00606662. PMID   3803419. S2CID   41004554.
  24. 1 2 Dilger RN, Baker DH (July 2007). "Oral N-acetyl-L-cysteine is a safe and effective precursor of cysteine". Journal of Animal Science. 85 (7): 1712–1718. doi:10.2527/jas.2006-835. PMID   17371789.
  25. ↑ Kanter MZ (October 2006). "Comparison of oral and i.v. acetylcysteine in the treatment of acetaminophen poisoning". American Journal of Health-System Pharmacy. 63 (19): 1821–1827. doi:10.2146/ajhp060050. PMID   16990628. S2CID   9209528.
  26. ↑ Dawson AH, Henry DA, McEwen J (March 1989). "Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning". The Medical Journal of Australia. 150 (6): 329–331. doi:10.5694/j.1326-5377.1989.tb136496.x. PMID   2716644. S2CID   40296724.
  27. ↑ Bailey B, McGuigan MA (June 1998). "Management of anaphylactoid reactions to intravenous N-acetylcysteine". Annals of Emergency Medicine. 31 (6): 710–715. doi:10.1016/S0196-0644(98)70229-X. PMID   9624310.
  28. ↑ Schmidt LE, Dalhoff K (January 2001). "Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning". British Journal of Clinical Pharmacology. 51 (1): 87–91. doi:10.1046/j.1365-2125.2001.01305.x. PMC   2014432 . PMID   11167669.
  29. ↑ Lynch RM, Robertson R (January 2004). "Anaphylactoid reactions to intravenous N-acetylcysteine: a prospective case controlled study". Accident and Emergency Nursing. 12 (1): 10–15. doi:10.1016/j.aaen.2003.07.001. PMID   14700565.
  30. ↑ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006.
  31. ↑ Tam J, Nash EF, Ratjen F, Tullis E, Stephenson A (12 July 2013). "Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis" (PDF). The Cochrane Database of Systematic Reviews. 2013 (7): CD007168. doi:10.1002/14651858.CD007168.pub3. PMC   8078644 . PMID   23852992. Archived from the original (PDF) on 27 March 2022. Retrieved 16 May 2018.
  32. ↑ Grandjean EM, Berthet P, Ruffmann R, Leuenberger P (February 2000). "Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials". Clinical Therapeutics. 22 (2): 209–21. doi:10.1016/S0149-2918(00)88479-9. PMID   10743980.
  33. ↑ Stey C, Steurer J, Bachmann S, Medici TC, Tramèr MR (August 2000). "The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review". The European Respiratory Journal. 16 (2): 253–262. doi: 10.1034/j.1399-3003.2000.16b12.x . PMID   10968500.
  34. ↑ Poole PJ, Black PN (May 2001). "Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review". BMJ. 322 (7297): 1271–1274. doi:10.1136/bmj.322.7297.1271. PMC   31920 . PMID   11375228.
  35. ↑ Garrett CE, Prasad K (2004). "The Art of Meeting Palladium Specifications in Active Pharmaceutical Ingredients Produced by Pd-Catalyzed Reactions". Advanced Synthesis & Catalysis. 346 (8): 889–900. doi:10.1002/adsc.200404071. S2CID   94929244.
  36. ↑ "Acetylcysteine", livertox.nih.gov, retrieved 26 April 2019
  37. ↑ Buijtels PC, Petit PL (July 2005). "Comparison of NaOH–N-acetyl cysteine and sulfuric acid decontamination methods for recovery of mycobacteria from clinical specimens". Journal of Microbiological Methods. 62 (1): 83–88. doi:10.1016/j.mimet.2005.01.010. PMID   15823396.
  38. ↑ Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, et al. (February 2010). "N-Acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus" (PDF). Biochemical Pharmacology. 79 (3): 413–420. doi:10.1016/j.bcp.2009.08.025. PMID   19732754.
  39. ↑ Aslam S, Darouiche RO (September 2011). "Role of antibiofilm-antimicrobial agents in controlling device-related infections". The International Journal of Artificial Organs. 34 (9): 752–758. doi:10.5301/ijao.5000024. PMC   3251652 . PMID   22094553.
  40. 1 2 "Mucomyst Package Insert". Archived from the original on 21 April 2014. Retrieved 20 April 2014.
  41. 1 2 Palmer LA, Doctor A, Chhabra P, Sheram ML, Laubach VE, Karlinsey MZ, et al. (September 2007). "S-Nitrosothiols signal hypoxia-mimetic vascular pathology". The Journal of Clinical Investigation. 117 (9): 2592–2601. doi:10.1172/JCI29444. PMC   1952618 . PMID   17786245.
  42. ↑ Hildebrandt W, Alexander S, Bärtsch P, Dröge W (March 2002). "Effect of N-acetyl-cysteine on the hypoxic ventilatory response and erythropoietin production: linkage between plasma thiol redox state and O2 chemosensitivity". Blood. 99 (5): 1552–5. doi: 10.1182/blood.V99.5.1552 . PMID   11861267. S2CID   24375953.
  43. ↑ Wang AL, Wang JP, Wang H, Chen YH, Zhao L, Wang LS, et al. (March 2006). "A dual effect of N-acetylcysteine on acute ethanol-induced liver damage in mice". Hepatology Research. 34 (3): 199–206. doi:10.1016/j.hepres.2005.12.005. PMID   16439183.
  44. ↑ "Product Information: Aceradote® Concentrated Injection" (PDF). TGA eBusiness Services. Phebra Pty Ltd. 16 January 2013. Archived from the original on 8 September 2017. Retrieved 8 November 2013.
  45. ↑ Steullet P, Neijt HC, Cuénod M, Do KQ (2006). "Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia". Neuroscience. 137 (3): 807–819. doi:10.1016/j.neuroscience.2005.10.014. ISSN   0306-4522. PMID   16330153. S2CID   1417873.
  46. 1 2 Varga V, Jenei Z, Janáky R, Saransaari P, Oja SS (1997). "Glutathione Is an Endogenous Ligand of Rat Brain N-Methyl-D-Aspartate (NMDA) and 2-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionate (AMPA) Receptors". Neurochemical Research. 22 (9): 1165–1171. doi:10.1023/A:1027377605054. ISSN   0364-3190. PMID   9251108. S2CID   24024090.
  47. ↑ Oja SS (2000). "Modulation of glutamate receptor functions by glutathione". Neurochemistry International. 37 (2–3): 299–306. doi:10.1016/S0197-0186(00)00031-0. ISSN   0197-0186. PMID   10812215. S2CID   44380765.
  48. 1 2 3 4 5 6 Berk M, Malhi GS, Gray LJ, Dean OM (March 2013). "The promise of N-acetylcysteine in neuropsychiatry". Trends in Pharmacological Sciences. 34 (3): 167–177. doi:10.1016/j.tips.2013.01.001. PMID   23369637.
  49. ↑ Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, et al. (August 2008). "Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients". Neuropsychopharmacology. 33 (9): 2187–2199. doi: 10.1038/sj.npp.1301624 . hdl: 10536/DRO/DU:30071388 . PMID   18004285.
  50. ↑ Dodd S, Dean O, Copolov DL, Malhi GS, Berk M (December 2008). "N-Acetylcysteine for antioxidant therapy: pharmacology and clinical utility". Expert Opinion on Biological Therapy. 8 (12): 1955–1962. doi:10.1517/14728220802517901. PMID   18990082. S2CID   74736842.
  51. ↑ Kupchik YM, Moussawi K, Tang XC, Wang X, Kalivas BC, Kolokithas R, et al. (June 2012). "The effect of N-acetylcysteine in the nucleus accumbens on neurotransmission and relapse to cocaine". Biological Psychiatry. 71 (11): 978–986. doi:10.1016/j.biopsych.2011.10.024. PMC   3340445 . PMID   22137594.
  52. 1 2 3 4 Dean O, Giorlando F, Berk M (March 2011). "N-Acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action". Journal of Psychiatry & Neuroscience. 36 (2): 78–86. doi:10.1503/jpn.100057. PMC   3044191 . PMID   21118657.
  53. ↑ "N-Acetyl-L-cysteine | C5H9NO3S". PubChem. National Center for Biotechnology Information, U.S. National Library of Medicine. Archived from the original on 16 August 2016. Retrieved 22 July 2016.
  54. ↑ Long J (6 May 2021). "Amazon confirms plans on removing NAC supplements" . Retrieved 21 September 2023.
  55. ↑ Long J (22 April 2021). "Amazon reportedly removes NAC-containing dietary supplements". Natural Products Inside.
  56. ↑ "Warning Letter". benjaminmcevoy.com. U.S. Food and Drug Administration.
  57. ↑ "FDA Sends Warning Letters to Seven Companies Illegally Selling Hangover Products".
  58. ↑ "FDA Releases Draft Guidance on Enforcement Discretion for Certain NAC Products".
  59. ↑ Long J (25 August 2022). "Amazon resumes sales of NAC supplements". Natural Products Insider. Retrieved 11 January 2023.
  60. 1 2 Head SI (29 October 2017). "Antioxidant therapy in a mouse model of Duchenne muscular dystrophy: some promising results but with a weighty caveat". The Journal of Physiology. 595 (23): 7015. doi:10.1113/jp275232. ISSN   0022-3751. PMC   5709324 . PMID   29034480.
  61. ↑ Gu F, Chauhan V, Chauhan A (January 2015). "Glutathione redox imbalance in brain disorders". Current Opinion in Clinical Nutrition and Metabolic Care. 18 (1): 89–95. doi:10.1097/MCO.0000000000000134. PMID   25405315. S2CID   25333289.
  62. 1 2 Bavarsad Shahripour R, Harrigan MR, Alexandrov AV (March 2014). "N-Acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities". Brain and Behavior. 4 (2): 108–122. doi:10.1002/brb3.208. PMC   3967529 . PMID   24683506.
  63. ↑ Bachert C, Hörmann K, Mösges R, Rasp G, Riechelmann H, Müller R, et al. (March 2003). "An update on the diagnosis and treatment of sinusitis and nasal polyposis". Allergy. 58 (3): 176–191. doi:10.1034/j.1398-9995.2003.02172.x. PMID   12653791. S2CID   35319457.
  64. ↑ Aitio ML (January 2006). "N-Acetylcysteine – passe-partout or much ado about nothing?". British Journal of Clinical Pharmacology. 61 (1): 5–15. doi:10.1111/j.1365-2125.2005.02523.x. PMC   1884975 . PMID   16390346.
  65. ↑ Williamson J, Doig WM, Forrester JV, Tham MH, Wilson T, Whaley K, et al. (September 1974). "Management of the dry eye in Sjogren's syndrome". The British Journal of Ophthalmology. 58 (9): 798–805. doi:10.1136/bjo.58.9.798. PMC   1215027 . PMID   4433493.
  66. ↑ Lindblad AC, Rosenhall U, Olofsson A, Hagerman B (November–December 2011). "The efficacy of N-acetylcysteine to protect the human cochlea from subclinical hearing loss caused by impulse noise: a controlled trial". Noise & Health. 13 (55): 392–401. doi: 10.4103/1463-1741.90293 . PMID   22122955.
  67. ↑ Edwards MJ, Hargreaves IP, Heales SJ, Jones SJ, Ramachandran V, Bhatia KP, et al. (November 2002). "N-acetylcysteine and Unverricht-Lundborg disease: variable response and possible side effects". Neurology. 59 (9): 1447–1449. doi:10.1212/wnl.59.9.1447. PMID   12427904.
  68. ↑ Ataxia with Identified Genetic and Biochemical Defects at eMedicine
  69. 1 2 3 4 5 6 McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM (2014). "Potential role of N-acetylcysteine in the management of substance use disorders". CNS Drugs. 28 (2): 95–106. doi:10.1007/s40263-014-0142-x. PMC   4009342 . PMID   24442756.
  70. ↑ Clinical trial number NCT02541422 for "Use of NAC in Alleviation of Hangover Symptoms – Study Results" at ClinicalTrials.gov
  71. ↑ Coppersmith V, Hudgins S, Stoltzfus J, Stankewicz H (June 2021). "The use of N-acetylcysteine in the prevention of hangover: a randomized trial". Scientific Reports. 11 (1): 13397. Bibcode:2021NatSR..1113397C. doi:10.1038/s41598-021-92676-0. PMC   8238992 . PMID   34183702. S2CID   235673455.
  72. ↑ De Flora S, Grassi C, Carati L (1 July 1997). "Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment". European Respiratory Journal. 10 (7): 1535–1541. doi: 10.1183/09031936.97.10071535 . PMID   9230243.
  73. ↑ Pistolesi V, Regolisti G, Morabito S, Gandolfini I, Corrado S, Piotti G, et al. (December 2018). "Contrast medium induced acute kidney injury: a narrative review". Journal of Nephrology. 31 (6): 797–812. doi:10.1007/s40620-018-0498-y. PMID   29802583. S2CID   44128861.
  74. ↑ "Hemorrhagic Cystitis Treatment & Management: Approach Considerations, Clot Evacuation, Bladder Irrigation Agents". 5 December 2019. Retrieved 18 December 2019.
  75. 1 2 3 Bartoli F, Cavaleri D, Bachi B, Moretti F, Riboldi I, Crocamo C, et al. (September 2021). "Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials". Journal of Psychiatric Research. 143: 230–238. doi:10.1016/j.jpsychires.2021.09.018. PMID   34509090. S2CID   237485915.
  76. ↑ Carollo M, Carollo N, Montan G (February 2024). "The promise of N-acetylcysteine in the treatment of obsessive-compulsive disorder". CNS Neuroscience & Therapeutics. 30 (2): e14653. doi:10.1111/cns.14653. PMC   10883097 . PMID   38385640.
  77. 1 2 3 Slattery J, Kumar N, Delhey L, Berk M, Dean O, Spielholz C, et al. (August 2015). "Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review". Neuroscience and Biobehavioral Reviews. 55: 294–321. doi: 10.1016/j.neubiorev.2015.04.015 . PMID   25957927.
  78. ↑ Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K, et al. (June 2014). "The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial". The Journal of Clinical Psychiatry. 75 (6): 628–636. doi: 10.4088/JCP.13m08454 . PMID   25004186.
  79. ↑ Oliver G, Dean O, Camfield D, Blair-West S, Ng C, Berk M, et al. (April 2015). "N-Acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review". Clinical Psychopharmacology and Neuroscience. 13 (1): 12–24. doi:10.9758/cpn.2015.13.1.12. PMC   4423164 . PMID   25912534.
  80. ↑ Samuni Y, Goldstein S, Dean OM, Berk M (August 2013). "The chemistry and biological activities of N-acetylcysteine". Biochimica et Biophysica Acta (BBA) - General Subjects. 1830 (8): 4117–4129. doi:10.1016/j.bbagen.2013.04.016. hdl: 11343/43874 . PMID   23618697. S2CID   2567773.
  81. ↑ Minarini A, Ferrari S, Galletti M, Giambalvo N, Perrone D, Rioli G, et al. (2 November 2016). "N-Acetylcysteine in the treatment of psychiatric disorders: current status and future prospects". Expert Opinion on Drug Metabolism & Toxicology. 13 (3): 279–292. doi:10.1080/17425255.2017.1251580. hdl: 11380/1116466 . PMID   27766914. S2CID   20873065.
  82. ↑ Hwang AS, Campbell EH, Sartori-Valinotti JC (July 2022). "Evidence of N-acetylcysteine efficacy for skin picking disorder: A retrospective cohort study". Journal of the American Academy of Dermatology. 87 (1): 148–150. doi: 10.1016/j.jaad.2021.06.874 . PMID   34224772. S2CID   235746237.
  83. ↑ Popova L, Mancuso J (2022). "Dramatic Improvement of Trichotillomania with 6 Months of Treatment With N-Acetylcysteine". Global Pediatric Health. 9: 2333794X221086576. doi:10.1177/2333794X221086576. PMC   9133858 . PMID   35647220.
  84. ↑ Nery FG, Li W, DelBello MP, Welge JA (November 2021). "N-acetylcysteine as an adjunctive treatment for bipolar depression: A systematic review and meta-analysis of randomized controlled trials". Bipolar Disorders. 23 (7): 707–714. doi:10.1111/bdi.13039. PMID   33354859. S2CID   229692736.
  85. ↑ Wong KK, Lee SW, Kua KP (2021). "N-Acetylcysteine as Adjuvant Therapy for COVID-19 – A Perspective on the Current State of the Evidence". Journal of Inflammation Research. 14: 2993–3013. doi: 10.2147/JIR.S306849 . PMC   8274825 . PMID   34262324.
  86. ↑ Assimakopoulos SF, Aretha D, Komninos D, Dimitropoulou D, Lagadinou M, Leonidou L, et al. (2021). "N-Acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study". Infectious Diseases (London, England). 53 (11): 847–854. doi:10.1080/23744235.2021.1945675. PMID   34182881. S2CID   235673520.
  87. ↑ Kapur A, Sharma M, Sageena G (2022). "Therapeutic potential of N-acetyl cysteine during COVID-19 epoch". World Journal of Virology. 11 (2): 104–106. doi: 10.5501/wjv.v11.i2.104 . PMC   8966593 . PMID   35433335.
  88. ↑ Fesharaki-Zadeh A, Lowe N, Arnstien A (2022). "Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in "Long-COVID19"". Neuroimmunology Reports. 3 (3): 100154. doi: 10.1016/j.nerep.2022.100154 .
  89. ↑ Kumar P, Osahon O, Vides DB, Hanania N, Minard CG, Sekhar RV (December 2021). "Severe Glutathione Deficiency, Oxidative Stress and Oxidant Damage in Adults Hospitalized with COVID-19: Implications for GlyNAC (Glycine and N-Acetylcysteine) Supplementation". Antioxidants. 11 (1): 50. doi: 10.3390/antiox11010050 . PMC   8773164 . PMID   35052554.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.